Skip to main content
. 2013 Jun;87(11):6073–6080. doi: 10.1128/JVI.00579-12

Fig 4.

Fig 4

A LTNP macaque targets APOBEC3F. (A) PBMC from a LTNP (with no detectable plasma virus) were screened against APOBEC3F pools predicted to bind Mamu-A1*001:01 or Mamu-A1*002:01, and the SIVmac239 Gag71-79 GY9 epitope in an IFN-γ ELISPOT. Results are shown as means plus standard deviations of duplicate wells. (B) A CD8+ T cell line was generated by multiple rounds of stimulation using the APOBEC3F Mamu-A1*002:01 pool C. The cell line reacts against the autologous B lymphocyte cell line (BLCL) presenting both the pool and the single epitope APOBEC3F115-125 LY11. Graphs were generated by gating on CD8+ cells. (C) Tetramers specific for either APOBEC3F115-125 LY11 or SIVmac239 Vif97-104 WY8 were used to stain cryopreserved PBMC, an in vitro CD8+ T cell line specific for Mamu-A1*002:01-restricted APOBEC3F115-125 LY11, and an in vitro CD8+ T cell clone specific for Mamu-A1*002:01-restricted SIVmac239 Vif97-104 WY8. Dot plots were generated by gating on CD3+ or CD8+ cells. The percentages of tetramer-positive events are shown. rhAJ11, recombinant human AJ11; WPI, weeks post-SIVmac239 infection.